Loading discussion content. Please wait...
Study: Minimum dose of hydromethylthionine could slow cognitive decline in mild-to-moderate Alzheimer's
Maybe some hope???
A clinical trial was just completed this year using methylene blue as a treatment for Alzheimers and the results were disappointing. Methylene blue, which earlier was found to inhibit tau aggregation in a mouse model, did not perform well on human patients.
TauRx sponsored a trial for its reformulation of methylene blue, which they named hydromethylthionine or LMTM, and it indicated that a low dosage of 8 mg/day showed the same reductions in cognitive decline and brain atrophy as the high dosages. Surprisingly the patients taking the high dosages of 150 to 250 mg faired no better than the low dose.
The concern is that the group given the low dose was also the placebo group. The placebo group was given the low dosage so that their urine would show up as blue, same as the high dose group, so that patients would not know if they were in the high dosage group or the placebo group.
The researchers were mistaken in thinking that 8 mg per day was so low that it would not have any therapeutic affect. So it turned out that there was no real placebo group to compare with the treated group, which creates the problem of determining the trials validity.
Why didn't they divide the patients into many different groups according to dosages, which would include a low dosage group. After all, as a research scientist, you would want to find the lowest effective dose so as to reduce bad side effects. It was only by accident that they discovered that a low dose might work.
A new clinical trial for LMTM using the the lower dose will have to be launched, this time making sure the placebo group is free of the trialed drug.
It is too bad that the methylene blue trial didn't work. It would have been a cheap treatment since it has been in use for more than a century. No company could claim exclusive right through patents. Still this drug has been shown to affect tau pathology and perhaps it could be trialed as a preventive, that is, if any company or organization were willing to trial a drug that could not be patented.
PattieR, I don't know why you can't see montelukast (Singulair) as a possible treatment. I have been taking this inexpensive anti-inflammatory drug for almost four years, and my extreme mental fatigue and occasional confusion were completely gone within a week of starting. I can't guarantee that it will work for you, but you can only know if you try. It is a very safe drug for adults, used by millions for over twenty years for asthma attack prevention. It is most effective if taken 10 mg at least twice a day. I myself have been taking it three times a day.
As I have said in earlier posts, Emory University in Atlanta, GA recently started a FDA clinical trial with this drug for early stage Alzheimers. It is being sponsored not by a drug company but rather Emory itself. Emory is paying out millions of dollars for this trial. It is very rare for a university to pay for a FDA trial, so evidently their researchers have confidence in a good outcome.
I like reading about the new drugs being considered as treatments for Alzheimers, but even if any of these drugs ever make it through the FDA trials, they won't be available for many, many years. A lot of information about these drugs in news articles originate from news releases from the drug companies, who are seeking higher stock prices and more investors, so you will get a lot of positives and few negatives.
So you can try montelukast now for a few weeks to a month and see if you get any benefit, or you can wait two more years for the Emory trial to be completed.
Of the ongoing clinical trials, Feru-guard (ferulic acid in rice bran and garden angelica) probably has the best chance of succeeding.
The scheduled completion date for the trial being conducted by the Oregon Health and Science University is this month, so hopefully data will be available in a few months.